Analysts expect Indaptus Therapeutics to report a consensus EPS loss of -$0.36 for Q2 2026 on zero revenue, with the stock currently trading at $1.56 against an average analyst price target of $11.00. Investors are primarily focused on the clinical progress and safety profile of the Phase 1 trial for DEC-201, the company's lead oncology candidate. Recent updates have highlighted the completion of the fourth dose cohort without dose-limiting toxicities, signaling a potential shift toward determining the recommended Phase 2 dose.
Management's commentary on the cash runway is also critical, as the company previously indicated sufficient funding to support operations into early 2025, suggesting a need for updates on capital strategy.